Información del artículo
El Texto completo está disponible en PDF
References
[1.]
L. Gorospe, J. Echebeste, S. Raman.
Tomografía por emisión de positrones/tomografía computarizada: artefactos y pitfalls en pacientes con cáncer.
Radiologia, 48 (2006), pp. 189-204
[2.]
M. Coronado, R. Couto, S. Rodado, L.M. Martín.
Semiología de la PET/TAC con 18F-FDG.
Rev Esp Med Nucl, 27 (2008), pp. 284-306
[3.]
C. Ansquer, S. Scigliano, E. Mirallié, D. Taïeb, L. Brunaud, F. Sebag, et al.
18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.
Eur J Nucl Med Mol, (2010),
[4.]
W. Giles, L. Boland, A. Michael, P.F. Hahn.
PET/CT for the Characterization of Adrenal Masses in Patients with Cancer: Qualitative Versus Quantitative Accuracy in 150 Consecutive Patients.
AJR., 192 (2009), pp. 956-962
[5.]
T enenbaum F, Groussin L, Foehrenbach H, et al. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients. J Clin Endocrinol Metab;94:1713–1722.
[6.]
M. Okada, T. Shimono, Y. Komeya, R. Ando, Y. Kagawa, T. Katsube, et al.
Adrenal masses: the value of additional fluorodeoxyglucosepositron emission tomography/computed tomography (FDGPET/CT) in differentiating between benign and malignant lesions.
Ann Nucl Med, 23 (2009), pp. 349-354
[7.]
W. Chen, M. Parsons, D. Torigian, H. Zhuang, A. Alavi.
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging.
Nuclear Medicine Communications, 30 (2009), pp. 240-244
[8.]
T. Bogsrud, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman, D.A. Collins, et al.
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET–CT.
Nuclear Medicine Communications, 28 (2007), pp. 373-381
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
